Do you know how the biosafety risks of oncolytic immunotherapies and their combination with immune checkpoint inhibitors can be mitigated?

Credit available for this activity expires: 6/22/24
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/993479?ecd=bdc_podcast_libsyn_mscpedu